Sturdy —

Apera AI offers 4D Vision technology for industrial robotics, enabling faster, more reliable, and scalable autonomous manufacturing.

Amperon is the leading energy forecasting company, positioned at the intersection of energy data and AI. Founded in 2018, Amperon has become a trusted partner to power and utility companies, delivering demand, renewable generation, and price forecasts. With cutting-edge predictive analytics, seamless data integrations, and premium customer support, Amperon enables customers to enhance grid reliability and optimize asset performance. Committed to grid modernization, Amperon is the forecasting company of the energy transition. Our mission is to forecast the energy transition and empower our customers to shape the future of Electrons on grids globally.

1 node is the AI agency enterprises choose to build AI solutions from prototype through production. It all starts with the first node.

We build infrastructure for autonomous businesses. Our AI agent systems handle marketing, content, and growth operations end-to-end, so teams can focus on strategy instead of execution.

We are forging the worlds most advanced mathematical reasoning engine

Instead of spending money on podcast ads, businesses like Basecamp, eBay, and Code Pen are using branded podcasts to reach their audience. Our goal? Make Transistor the best way for a business to create a podcast. Currently, we offer podcast hosting. The user uploads their MP3, adds show notes and artwork, and we generate a podcast episode. This is syndicated via RSS, iTunes, and on their podcast website.

Sequence is the modern billing and quote to cash platform to unlock error-free revenue workflows at scale. Backed by a16z 645 ventures and Salesforce Ventures, Sequence is working with leading B2B scaleups including Cognition, Incident.io, Bridge (acq. by Stripe) OpenRouter and Legora.

52North is a medical technology company on a mission to make urgent care pathways safer and more effective. Awarded breakthrough status for its first product Neutrocheck® by the UK Government in 2024, 52North builds in vitro diagnostic and digital solutions to transform patient journeys in urgent care. Its award-winning, multidisciplinary team is based in Cambridge, UK. 52North is backed by leading UK and US hospital venture funds, Meridian Health Ventures and Cedars-Sinai Intellectual Property company, and other partners, including the University of Cambridge and Macmillan Cancer Support.